Premium
Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis
Author(s) -
Syrjala Karen L.,
Sutton Steven K.,
Jim Heather S. L.,
Knight Jennifer M.,
Wood William A.,
Lee Stephanie J.,
Jacobsen Paul B.,
Abidi Muneer H.,
Yi Jean C.
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30454
Subject(s) - medicine , distress , transplantation , quality of life (healthcare) , cronbach's alpha , cancer , discriminant validity , psychometrics , randomized controlled trial , hematopoietic cell , clinical psychology , physical therapy , internal consistency , nursing , stem cell , haematopoiesis , biology , genetics
BACKGROUND Routine monitoring of cancer‐related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer‐specific measures have been developed to date to assess the multiple cancer‐related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients. METHODS As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient‐reported outcomes including the CTXD and the Medical Outcomes Study Short Form‐36 (SF‐36) before transplantation and 100 days and 180 days after HCT. RESULTS Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were .94, .95, and .95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α = .77). Correlations with the SF‐36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF‐36 Mental Health subscale supported predictive validity. CONCLUSIONS The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416–1423. © 2016 American Cancer Society .